time to pursue independent, personal interests—that Dr. Hidvegi picked up where Szent-Györgyi left off.

But when Hidvegi’s funding ran out, it seemed as if the research would once again be set aside. He had

no money, he had no prospects, and his wife insisted he give up his research and find a paying job.

They were desperate. Yet he did still have one thing at that time—faith. Being a devout man, Dr.

Hidvegi prayed to the Virgin Mary for guidance—and an investor.

Miraculously, the very next day a stranger wrote Hidvegi a check for $100,000.

With that money, he was finally able to patent a technique of fermenting wheat germ with baker’s yeast.

He named this fermented product Avemar in tribute to the Virgin Mary (Ave meaning greetings and Mar

meaning Mary). It became the standard compound for research and later commercialization because it

assured a longer shelf life while maintaining its live food status.

Avemar is supported by more than 100 reports (written for presentation or publication) conducted in

the U.S., Hungary, Russia, Australia, Israel, and Italy and is validated by the publication of more than 20

peer-reviewed publications describing in vitro, in vivo, and human clinical trials.

Since 1996, over 100 studies done on Avemar have impressed oncologists and cancer researchers.

Studies have shown that when Avemar is used as an adjunct treatment, it enhances the effects of the standard

treatment agents. It’s particularly effective in reducing the chances of cancer recurrence.

In a controlled study, 170 subjects with primary colorectal cancer either had surgery and standard care

with chemotherapy or the same plus 9 g of Avemar taken once a day. Only 3 percent of the people in the

the Avemar group experienced a recurrence, vs. more than 17 percent of those in the chemo-only group. The

In a randomized study, 46 stage III melanoma patients with a high risk of recurrence either had surgery

and standard care with chemotherapy or surgery plus standard care and 9 g of Avemar taken once a day. Those

taking Avemar showed approximately a 50 percent

In a one-year, non-randomized trial of 43 patients with oral cancer, 21 patients received surgery and

standard care while 22 others received the same plus Avemar. The Avemar group showed an 85 percent

reduced risk of overall progression. Plus, only 4.5 percent of the patients in the Avemar group experienced

local recurrences as opposed to more than 57 percent of the people in the standard care group.

Avemar also reduced the frequency and severity of many common side effects, including nausea, fatigue,

weight loss, and immune suppression.

One of Avemar’s most unique benefits is that it cuts off cancer cells’ energy supply by selectively inhibiting

glucose metabolism. Cancer cells love glucose: It fuels the voracious growth and spread of tumors. In fact,

cancer cells utilize glucose at a 10- to 50-times higher rate than normal cells do.

Cancer cells that have a higher rate of glucose utilization have a greater chance of spreading. It’s on

these cells that we see Avemar’s most dramatic effects.

In fact, the greater the metastatic potential of the cancer cell line tested, the higher the glucose utilization

rate and the more dramatic Avemar’s effect.

Typical cancer treatments like chemotherapy kill off all cells—cancerous and healthy ones alike. But

because of how Avemar interacts with glucose, it can selectively attack cancer cells while leaving healthy

cells alone. Studies have shown that it would take a 50 times higher concentration of Avemar than is in a

normal therapeutic dose to inhibit glucose utilization in normal healthy cells.

The second way Avemar works against cancer is to keep cancer cells from repairing themselves. Can-

cer cells reproduce quickly and chaotically, producing many breaks and other mistakes in the cellular structure.

Because of this, cancer cells need a lot of the enzyme known as PARP (poly-ADP-ribose) to repair

breaks in DNA before the cells divide. Without adequate PARP, cancer cells cannot complete DNA replication.

When there’s no PARP to repair the damage, an enzyme called Caspase-3 initiates programmed cell

death.

Avemar has been shown to speed up the death of

Researchers at UCLA also showed that Avemar reduces the production of RNA and DNA associated

with the rapid reproduction of cancer cells. It also restores normal pathways of cell metabolism and

Avemar also acts as a biological bounty hunter for disguised cancer cells. Healthy cells have a surface

molecule called MHC-1 that tells natural killer (NK) cells not to attack. Virally infected cells don’t display

this molecule, which makes them targets. But cancer cells have also been shown to display

the surface molecule MHC-1, which means that cancer cells can actually hide from NK cells. Avemar

helps the immune system identify cancer cells for attack by suppressing their ability to generate this

Possibly one of the most powerful studies on Avemar shows its effectiveness on children with cancer.

Most forms of pediatric cancer have high cure rates from chemotherapy as compared with adult cancers,

but one of the limiting factors in using chemotherapy to treat children is the infection that can often occur

during treatment.

Infection often sets in because chemotherapy kills large numbers of the child’s infection-fighting white

blood cells and destroys many of the bone marrow cells that produce them.

Doctors aware of the immune-enhancing properties of Avemar wanted to learn if it could possibly

prevent the life-threatening infections that often occur in pediatric cancer patients.

such infections and the fever that accompanies them (called febrile neutropenia) were reduced by 42 percent

Avemar has this effect because it helps rebuild the immune system, increasing the number and activity

of functioning immune system cells. It’s clear that, unlike conventional cancer therapy, Avemar does not

produce side effects—it reduces them. It also allowed the children in the study to take more cycles of

chemotherapy, increasing the chance of a cure.

As dangerous as Avemar is for cancer cells, it won’t harm the rest of your body. In fact, according to an

In Hungary, where it was developed and is manufactured, it is classified as a “dietary food for special

medical purposes, for cancer patients” and is a standard therapy for patients with cancer. It is available

as a food or dietary supplement in several other countries as well, including Austria, Australia, Switzerland,

Italy, Slovakia, Czech Republic, Russia, Israel, and South Korea.

Avemar is made using a patented process that yields a uniform, consistent, all-natural dietary supplement.

Although it is not certified organic, it is free of chemicals and synthetics. According to

American BioSciences, the exclusive North American distributor of Avemar, there is simply no

comparison between their product and other wheat germ products on the market because it is the only

one supported by research demonstrating its effectiveness in maintaining normal, healthy cellular metabo-

But since this is a wheat product, there is the potential for allergic response. Although the process

of making the product removes all gluten, the principal allergen in wheat, the product can still come in

contact with gluten-containing wheat. American Bio-Sciences says that Avemar should not be consumed

by people who have had an organ or tissue transplant, those who have malabsorption syndrome, or those

with allergies to foods containing gluten, such as wheat, rye, oats, and barley.

It’s also not recommended for people with fructose intolerance or hypersensitivity to gluten, wheat germ, or

any of the components or ingredients of this product.

If you suffer from bleeding ulcers, you should stop using Avemar two days before undergoing a barium

X-ray contrast examination and resume taking it two days after the completion of the examination.

This precaution is necessary because wheat germ contains lectin, which can potentially cause red bloods

cells to clump.

If you are currently taking medications or have any adverse health conditions, you should consult with

your pharmacist or physician before taking Avemar.

The Avemar product at American BioSciences  is an instant drink mix called Avé,

which combines Avemar with natural orange flavoring and fructose in pre-measured packets.

As a dietary supplement, the recommended usage is one packet per day mixed with 8 oz. of cold water

(or any other beverage containing less than 10 mg of vitamin C). I found that the best way to mix it is to

shake it in a closed container. When I tried it, it reminded me of Tang, though it wasn’t quite as sweet.

You should consume it within 30 minutes of mixing a batch. Also note that it’s a good idea to take Avé

one hour before or after a meal and two hours before or after any drugs or other dietary supplements.

If you weigh over 200 pounds, use two packets per day. If you weigh under 100 pounds, only use

half of a packet per day. Consult with a healthcare professional for recommended usage levels for children,

for guidance on alternative usage levels, and for use in combination with other dietary supplements.

Most people who use Avé daily notice an effect within three weeks, reporting improvements in

appetite, energy, and general quality of life. If you work with your health care professional to

use Avé as an adjunct cancer treatment, you should know that it will take a good three months before

you will see a change in objective measurements—such as blood markers, CAT scans, MRIs, etc.

Although some people reported uneasiness in their stomachs during the first few days of using Avemar,

the effect only lasted a few days. No vomiting, diarrhea, or any other symptoms were reported.